Simvastatin

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet.

12.1 Mechanism of Action Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.

Systemic exposure to Simvastatin reflects Estimated 77%–89% oral systemic absorption for Simvastatin absorption kinetics and hepatic oxidation via cyp3a4 followed by renal and biliary excretion of simvastatin metabolites, sustaining receptor engagement across a Approximately 9–17 hours terminal plasma half-life for Simvastatin half-life window (peak plasma concentration (tmax) reached 1–4 hours post-dose for simvastatin response profile).

Dosing protocols (10 mg/1 Tablet, Film Coated or 80 mg/1 Tablet, Film Coated or 5 mg/1 Tablet, Film Coated or 20 mg/1 Tablet, Film Coated or 40 mg/1 Tablet, Film Coated) balance efficacy (92.00% patient satisfaction across 5 logs) against nausea (11.4% of reports), headache (10% of reports), nasopharyngitis (8.1% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to simvastatin or simvastatin excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2021-12-13 simvastatin spl.